Last reviewed · How we verify
Syntocinon
At a glance
| Generic name | Syntocinon |
|---|---|
| Also known as | Intranasal Oxytocin, Oxytocin, Intranasal oxytocin, oxytocin |
| Sponsor | Shana McCormack, MD |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage (PHASE4)
- 3-hour Versus 12-hour Double-balloon Catheter for Labor Induction: a Randomized Trial (NA)
- The Stimulation To Induce Mothers Study (PHASE4)
- Improving Safe Vaginal Deliveries for Delivering Mothers by Implementing an Intervention Package of 11 Evidence-based Practices and Robson Classification at a Semi-urban Hospital in Dhaka, Bangladesh (NA)
- Oxytocin to Treat PTSD (PHASE2)
- EVALUATİON OF THE EFFECTİVENESS OF A MODEL-BASED HYPNOBREASTFEEDİNG EDUCATİON PROGRAM GİVEN TO PRİMİPAROUS PREGNANT WOMEN (NA)
- Oxytocin Effects on Bone in Children With Autism Spectrum Disorder (PHASE2)
- Intra-Umbilical Vein Oxytocin Injection as an Adjunct to Active Management of the Third Stage of Labour (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Syntocinon CI brief — competitive landscape report
- Syntocinon updates RSS · CI watch RSS
- Shana McCormack, MD portfolio CI